scholarly journals Effect of Delta-Tocotrienol on Melanin Content and Enzymes for Melanin Synthesis in Mouse Melanoma Cells

2010 ◽  
Vol 33 (9) ◽  
pp. 1471-1476 ◽  
Author(s):  
Akihiro Michihara ◽  
Saki Ogawa ◽  
Yohei Kamizaki ◽  
Kenji Akasaki
2009 ◽  
Vol 55 (2) ◽  
pp. 314-318 ◽  
Author(s):  
Akihiro Michihara ◽  
Sachiyo Morita ◽  
Yae Hirokawa ◽  
Saya Ago ◽  
Kenji Akasaki ◽  
...  

Life Sciences ◽  
1992 ◽  
Vol 51 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Lisha Zhang ◽  
Takemi Yoshida ◽  
Yukio Kuroiwa

Cosmetics ◽  
2019 ◽  
Vol 6 (1) ◽  
pp. 9
Author(s):  
Eun Ji Lee ◽  
Hwa Jun Cha

Melanogenesis is a biosynthetic pathway that produces the pigment melanin in human skin. The catalyzation of the key enzyme tyrosinase is the first step in melanogenesis, and the downregulation of tyrosinase enzyme activity is the most reported method for inhibiting melanogenesis. Hyperpigmentation is an important issue in the cosmetic industry, and there is great demand for melanogenesis inhibitors. In the present study, we demonstrated the anti-melanogenic effect of Inonotus obliquus in alpha-melanocyte-stimulating hormone (α-MSH)-induced B16F10 mouse melanoma cells and identified it as a new melanogenesis inhibitor. Comparing the B16F10 cells treated with the control and the Inonotus obliquus extract, we identified the melanin contents, mRNA and protein expression of tyrosinase, tyrosinase activity, and microphthalmia-associated transcription factor (Mitf) activity using a constructed plasmid. Through these experiments, we confirmed that Inonotus obliquus extract inhibits melanin synthesis by downregulating the activity and expression of tyrosinase. Furthermore, we revealed that tyrosinase expression is regulated by Inonotus obliquus extract via the repression of Mitf transcriptional activity. Thus, in this study, we found that Inonotus obliquus extract has anti-melanogenic effects via the suppression of melanin synthesis. Taken together, we demonstrated that Inonotus obliquus extract is a good potential candidate for use as a natural source for the therapeutic treatment of hyperpigmentation and for applications in whitening cosmetic products.


2010 ◽  
Vol 74 (3) ◽  
pp. 579-582 ◽  
Author(s):  
Ichiro SHIRASUGI ◽  
Miyuki KAMADA ◽  
Takashi MATSUI ◽  
Yoichi SAKAKIBARA ◽  
Ming-Cheh LIU ◽  
...  

Cosmetics ◽  
2020 ◽  
Vol 7 (3) ◽  
pp. 61
Author(s):  
Shilpi Goenka ◽  
Sanford R. Simon

Skin hyperpigmentation disorders arise due to aberrant regulation of melanin synthesis and export. Current treatments include natural compounds like kojic acid and hydroquinone, which suffer from limitations due to adverse reactions. Thermorubin (TR) is a secondary metabolite derived from the fungus Thermoactinomyces antibioticus and has previously demonstrated to possess anti-inflammatory properties by inhibition of matrix metalloproteinases (MMPs), as well as antimicrobial activity. In the current study, we explored whether TR might be a used as a candidate for the treatment of skin hyperpigmentation disorders by studying its effects on melanin synthesis and melanin export in B16F10 mouse melanoma cells and primary human melanocytes derived from darkly-pigmented (DP) skin. Non-toxic doses of TR were first identified in B16F10 mouse melanoma cells. These doses were subsequently tested for their effects on both extracellular and intracellular melanin levels under conditions of basal and hormone-stimulated melanogenesis. Our results demonstrated that TR at 25 µM inhibited total melanin levels with selective inhibition of extracellular melanin in B16F10 cells under both basal and hormone-stimulated conditions. The mechanisms of inhibition did not include tyrosinase inhibition, either in cellular lysates or cell-free system. However, TR potently inhibited activity of α-glucosidase enzyme in vitro and exhibited antioxidant activity. Furthermore, our results with primary human melanocytes from DP skin showed that TR at 10 µM significantly suppressed dendricity along with an increase in accumulation of intracellular melanin. These findings point to a mechanism of action of TR as an exclusive inhibitor of melanosome export. Taken together, our preliminary results demonstrate that TR might offer a novel ingredient as a skin depigmenting agent for inclusion in cosmetic formulations. Further studies delineating molecular mechanisms of hypopigmentation of TR and testing in human skin tissue-equivalents are warranted.


2019 ◽  
Vol 819 ◽  
pp. 157-162
Author(s):  
Pokchut Kusolkumbot ◽  
Khaunnapa Panapong ◽  
Krongkarn Kingkeaw ◽  
Surada Soonthornsatitwong ◽  
Somkamol Manchun ◽  
...  

In this study, astaxanthin (ASTA), with potential anti-tyrosinase and anti-melanin synthesis in melanoma cells (B16F10) was developed as a cosmetic ingredient in the form of microemulsions (MEs). The results showed that ASTA (1 mg/mL) had no toxic effects on melanoma cells and it exhibited high potential for reduction of tyrosinase and melanin content, representing 80.57% and 75.86%, respectively. However, the use of ASTA is limited due to its low stability resulting from its decomposition under light, heat, and oxygen. In order to overcome this drawback, ASTA was encapsulated within ME. ASTA-MEs, consisting of 0.5% w/w of ASTA, oil, surfactant and water, were prepared using titration method.The effect of IPM concentration into microemulsions were investigated at 10 % w/w (ASTA-ME1) and 20% w/w (ASTA-ME2). The physical stability after accelerated condition of all the formulations was also investigated. The results indicated that a thermodynamically stable of microemulsion could improve the physical stability of ASTA. Nonetheless, the oil concentration had a slight influence on the physical stability of ASTA-ME1 and ASTA-ME2. In conclusion, nanoencapsulation can improve the physical stability of pigment extract to be used as a cosmetic ingredient in skin brightening products.


Biomolecules ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 674
Author(s):  
Shilpi Goenka ◽  
Francis Johnson ◽  
Sanford R. Simon

Skin hyperpigmentation disorders arise due to excessive production of the macromolecular pigment melanin catalyzed by the enzyme tyrosinase. Recently, the therapeutic use of curcumin for inhibiting tyrosinase activity and production of melanin have been recognized, but poor stability and solubility have limited its use, which has inspired synthesis of curcumin analogs. Here, we investigated four novel chemically modified curcumin (CMC) derivatives (CMC2.14, CMC2.5, CMC2.23 and CMC2.24) and compared them to the parent compound curcumin (PC) for inhibition of in vitro tyrosinase activity using two substrates for monophenolase and diphenolase activities of the enzyme and for diminution of cellular melanogenesis. Enzyme kinetics were analyzed using Lineweaver-Burk and Dixon plots and nonlinear curve-fitting to determine the mechanism for tyrosinase inhibition. Copper chelating activity, using pyrocatechol violet dye indicator assay, and antioxidant activity, using a DPPH radical scavenging assay, were also conducted. Next, the capacity of these derivatives to inhibit tyrosinase-catalyzed melanogenesis was studied in B16F10 mouse melanoma cells and the mechanisms of inhibition were elucidated. Inhibition mechanisms were studied by measuring intracellular tyrosinase activity, cell-free and intracellular α-glucosidase enzyme activity, and effects on MITF protein level and cAMP maturation factor. Our results showed that CMC2.24 showed the greatest efficacy as a tyrosinase inhibitor of all the CMCs and was better than PC as well as a popular tyrosinase inhibitor-kojic acid. Both CMC2.24 and CMC2.23 inhibited tyrosinase enzyme activity by a mixed mode of inhibition with a predominant competitive mode. In addition, CMC2.24 as well as CMC2.23 showed a comparable robust efficacy in inhibiting melanogenesis in cultured melanocytes. Furthermore, after removal of CMC2.24 or CMC2.23 from the medium, we could demonstrate a partial recovery of the suppressed intracellular tyrosinase activity in the melanocytes. Our results provide a proof-of-principle for the novel use of the CMCs that shows them to be far superior to the parent compound, curcumin, for skin depigmentation.


Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 1066
Author(s):  
Ali Zari ◽  
Hajer Alfarteesh ◽  
Carly Buckner ◽  
Robert Lafrenie

Uncaria tomentosa is a medicinal plant native to Peru that has been traditionally used in the treatment of various inflammatory disorders. In this study, the effectiveness of U. tomentosa as an anti-cancer agent was assessed using the growth and survival of B16-BL6 mouse melanoma cells. B16-BL6 cell cultures treated with both ethanol and phosphate-buffered saline (PBS) extracts of U. tomentosa displayed up to 80% lower levels of growth and increased apoptosis compared to vehicle controls. Treatment with ethanolic extracts of Uncaria tomentosa were much more effective than treatment with aqueous extracts. U. tomentosa was also shown to inhibit B16-BL6 cell growth in C57/bl mice in vivo. Mice injected with both the ethanolic and aqueous extracts of U. tomentosa showed a 59 ± 13% decrease in B16-BL6 tumour weight and a 40 ± 9% decrease in tumour size. Histochemical analysis of the B16-BL6 tumours showed a strong reduction in the Ki-67 cell proliferation marker in U. tomentosa-treated mice and a small, but insignificant increase in terminal transferase dUTP nick labelling (TUNEL) staining. Furthermore, U. tomentosa extracts reduced angiogenic markers and reduced the infiltration of T cells into the tumours. Collectively, the results in this study concluded that U. tomentosa has potent anti-cancer activity that significantly inhibited cancer cells in vitro and in vivo.


Sign in / Sign up

Export Citation Format

Share Document